AICUBE signs agreement with Prima Lab SA

AICUBE and Prima Lab are strategic partners in the development of DOC.D©, an innovative non- invasive device for measuring salivary glucose in type II diabetic patients.

Milan September 19th, 2022 - Milan-based innovative startup AICUBE, strongly oriented towards proactive prevention and predictive medicine through Machine Learning algorithms, has signed a contract with Prima Lab, a company developing and manufacturing medical diagnostic tests and components with a recognised international experience, as its industrial partner for our DOC.D© device.

In 2021, AICUBE achieved important research and development goals for the device. It has therefore begun the industrialisation process that will take it to the next stage of industrial prototyping. The relationship with Prima Lab stems from an intense period of evaluation of different companies in the diagnostics field with the aim of finding the best partner for this important phase of the company. Prima Lab is the fourth company, after DAOS, PQ Design Group and Bartels, with which AICUBE has decided to collaborate on the DOC.D© project.

Prima Lab is a Swiss company founded by an Italian entrepreneur with a lengthy experience in the diagnostic field. PRIMA from its initial origins back in 2014 has grown to become an international player with a wide array of diagnostic tests, both for home as well as professional and point-of- care use. PRIMA has its own R&D activities as well as state of the art manufacturing capabilities.

The DOC.D© device development project involves several phases and the entry of new industrial partners to achieve our goal of increasing the level of secondary prevention. There is in fact the possibility of making an early diagnosis of diseases which, if diagnosed in time, can be cured or their associated complications reduced.

Secondary prevention can be implemented by collecting the values of specific biomarkers on a daily or weekly basis to obtain statistically significant data.

We have therefore patented a device that non-invasively collects a saliva sample using an 'augmented' electric toothbrush. The saliva sample is then moved to a unit (base) that measures the value of the reference biomarker such as glucose for type II diabetes or salivary cholesterol

AICUBE signs an agreement with DAOS Group for industrial design.

AICUBE and DAOS Group strategic partners for the development of DOC.D^©, an innovative non-invasive device for the measurement of salivary glucose in type II diabetic patients.

Milan April 14th, 2022 - AICUBE innovative startup, based in Milan, strongly oriented to proactive prevention and predictive medicine through Machine Learning algorithms, has signed a contract with DOAS Group Hardware and Software design company in the electronic design, firmware, and software development of our DOC.D^© device.

In 2021, AICUBE reached important goals in research, development of the device. It has therefore started the industrialization process that will lead it to the next stage of industrial prototyping. The relationship with DAOS Group comes after an intense period of evaluation of different companies in the field of applied electronics, IOT and Cloud with the aim of finding the best partner for this important phase of the company. DAOS Group is the third company, after PQ Design Group and Bartels, with which AICUBE decides to collaborate on the DOC.D© project.

DAOS Group is an Italian company formed by a group of professionals in the sector, active for over 30 years and with skills and recognition at an international level, which has created an avant-garde reality made up of specialized technicians. Able to innovate in terms of methodology and organization. Together with our partners DAOS has created a network capable of proposing original ideas and high-quality services: conceiving, designing, and implementing innovative solutions. The activities of the DAOS Group are divided into four macro areas of intervention: hardware design, software design, mechanical design, prototyping and production.

The DOC.D© device development project involves several phases and the entry of new industrial partners to achieve our goal of increasing the level of secondary prevention. There is in fact the possibility of making an early diagnosis of diseases which, if diagnosed in time, can be cured or their associated complications reduced.

Secondary prevention can be implemented by collecting the values of specific biomarkers on a daily or weekly basis to obtain statistically significant data.

We have therefore patented a device that non-invasively collects a saliva sample using an 'augmented' electric toothbrush. The saliva sample is then moved to a unit (base) that measures the value of the reference biomarker such as glucose for type II diabetes or salivary cholesterol

AICUBE signs an exclusive license agreement with the Istituto Italiano di Tecnologia concerning the Italian patent no. IT001403160 and European patent no. EP 2648866 on the invention entitled

"Procedure for the synthesis of stellate gold nanoparticles with controlled dimensions and branching and stellate gold nanoparticles thus obtained"

(MAIORANO, GABRIELE; RIZZELLO, LORIS; SANGARU, SHIV SHANKAR; CINGOLANI, ROBERTO; POMPA, PIER PAOLO)

AICUBE and IIT are strategic partners in the development of DOC.D©, an innovative non-invasive device for measuring salivary glucose.

Milan 8 November 2021 - Milan-based innovative startup AICUBE, strongly oriented towards proactive prevention and predictive medicine through Machine Learning algorithms, has signed a contract with researchers from the "Nanobiointeractions and Nanodiagnostics" team of the Italian Institute of Technology (IIT), led by Pierpaolo Pompa, which operates at the Institute's headquarters in Genoa, the largest research infrastructure in the entire IIT network and where the Foundation started its activities in 2006.

In 2021 AICUBE achieved important goals in research, device development and capital raising. It has therefore started the industrialization process that will lead it to the next stage of industrial prototyping. The relationship with IIT continues with mutual satisfaction in the development and industrialization of the colorimetric sensor for the measurement of salivary glucose whose technology is the basis of our device.

The Italian Institute of Technology (IIT) is a state-funded scientific research centre that promotes technological development with the aim of supporting excellence in basic and applied research to foster the development of the national economic system. IIT's research activity is characterized by a strong multidisciplinary approach and covers four scientific areas: robotics, computational science, life science technologies and nanomaterials.

The DOC.D© device development project involves several phases and the entry of new industrial partners to achieve our goal of increasing the level of secondary prevention. There is in fact the possibility of making an early diagnosis of diseases which, if diagnosed in time, can be cured or their associated complications reduced.

Secondary prevention can be implemented by collecting the values of specific biomarkers on a daily or weekly basis to obtain statistically significant data.

We have therefore patented a device that non-invasively measures salivary glucose in type II diabetic patients on a daily basis in order to characterise its trend. The aim of this important collaboration is to industrialise the sensor that measures changes in this important parameter.

AICUBE signs an agreement with Datamantix for the feasibility study and prototyping of Artificial Intelligence in the characterization of vibrations in Parkinson's patients.

AICUBE and Datamantix are strategic partners for the development of DOC.D©, an innovative non-invasive device that aims to characterize the vibrations of Parkinson's patients using Data Science and Machine Learning techniques.

Milan 5 October 2021 - AICUBE innovative startup, based in Milan, strongly oriented towards proactive prevention and predictive medicine through Machine Learning algorithms, has signed a contract with Datamantix innovative startup, based in Udine, Italy, which deals with the design and development of advanced Artificial Intelligence systems.

In 2021, AICUBE achieved important goals in research, device development and capital raising. It has therefore begun the industrialization process that will take it to the next stage of industrial prototyping. The relationship with Datamantix is the result of an intense period of evaluation of various companies in the field of industrial design with the aim of finding the best partner for this important phase of the company.

Datamantix S.r.l., founded by PhDs in Computer Science with international experience in Artificial Intelligence and Software Engineering, develops advanced technological systems to enable its customers to exploit the potential of their data, knowledge, and skills.

The DOC.D© device development project involves several phases and the entry of new industrial partners to achieve our goal of increasing the level of secondary prevention. In fact, there is the possibility of making an early diagnosis of diseases which, if diagnosed in time, can be cured or their associated complications reduced.

Secondary prevention can be implemented by collecting the values of specific biomarkers on a daily or weekly basis to obtain statistically significant data.

We have therefore patented a "smart" toothbrush that non-invasively measures tremor in parkinsonian patients on a daily basis in order to characterize its progress. The aim of this important collaboration is to find the Machine Learning algorithm that best determines the variations of this important evaluation parameter.